Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters

Radiotherapy and Oncology

Volumn 109, Issue 1, 2013, Pages 58-64

  Zegers, Catharina M L ^a   Van Elmpt, Wouter ^a   Wierts, Roel ^a   Reymen, Bart ^a   Sharifi, Hoda ^a   Öllers, Michel C ^a   Hoebers, Frank ^a   Troost, Esther G C ^a   Wanders, Rinus ^a   Van Baardwijk, Angela ^a   Brans, Boudewijn ^a   Eriksson, Jonas ^b   Windhorst, Bert ^b   Mottaghy, Felix M ^a,c   De Ruysscher, Dirk ^a,d   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Hx4; Hypoxia; Imaging; Nsclc; Pet

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; 3 [FLUORO 2 [4 [(2 NITRO 1H IMIDAZOL 1 YL]METHYL] 1H 1,2,3 TRIAZOL 1 YL]PROPAN 1 OL F 18; ANTINEOPLASTIC AGENT; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; HX4 COMPOUND; IMIDAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST TO NOISE RATIO; CONTROLLED STUDY; DRUG UPTAKE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HYPOXIA; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; SPATIOTEMPORAL ANALYSIS; CELL HYPOXIA; HX4; IMAGING; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; NSCLC; PATHOLOGY; PET; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

HX4; HYPOXIA; IMAGING; NSCLC; PET;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TRIAZOLES;

EID: 84888058346     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.08.031     Document Type: Article

References (39)

1. A. van Baardwijk, B. Reymen, and S. Wanders Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer Eur J Cancer 48 2012 2339 2346
2. B.G. Wouters, T. van den Beucken, M.G. Magagnin, P. Lambin, and C. Koumenis Targeting hypoxia tolerance in cancer Drug Resist Updat 7 2004 25 40
3. P. Lambin, R.G. van Stiphout, and M.H. Starmans Predicting outcomes in radiation oncology - multifactorial decision support systems Nat Rev Clin Oncol 10 2013 27 40
4. J. Overgaard Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck - a systematic review and meta-analysis Radiother Oncol 100 2011 22 32
5. L.S. Mortensen, J. Johansen, and J. Kallehauge FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial Radiother Oncol 105 2012 14 20
6. S.M. Eschmann, F. Paulsen, and M. Reimold Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy J Nucl Med 46 2005 253 260
7. 18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study BMC Cancer 6 2006 51
8. P. Vera, P. Bohn, and A. Edet-Sanson Simultaneous positron emission tomography (PET) assessment of metabolism with (1)(8)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (1)(8)F-fluoro-thymidine (FLT), and hypoxia with (1)(8)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study Radiother Oncol 98 2011 109 116
9. M.I. Bittner, N. Wiedenmann, and S. Bucher Exploratory geographical analysis of hypoxic subvolumes using F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy Radiother Oncol 2013 epub ahead of print
10. V.R. Bollineni, G.S. Kerner, and J. Pruim PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients J Nucl Med 54 2013 1 6
11. D. Zips, S. Boke, and T. Kroeber Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control Strahlenther Onkol 187 2011 306 310
12. P. Lambin, S.F. Petit, and H.J. Aerts The E.S.T.R.O. Breur. Lecture from population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer Radiother Oncol 2010 2009 145 152
13. K. Hendrickson, M. Phillips, W. Smith, L. Peterson, K. Krohn, and J. Rajendran Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance Radiother Oncol 101 2011 369 375
14. D. Thorwarth, S.M. Eschmann, F. Paulsen, and M. Alber Hypoxia dose painting by numbers: a planning study Int J Radiat Oncol Biol Phys 68 2007 291 300
15. W. van Elmpt, D. De Ruysscher, and A. van der Salm The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer Radiother Oncol 104 2012 67 71
16. V.R. Bollineni, E.M. Wiegman, J. Pruim, H.J. Groen, and J.A. Langendijk Hypoxia imaging using positron emission tomography in non-small cell lung cancer: implications for radiotherapy Cancer Treat Rev 38 2012 1027 1032
17. M.R. Horsman, L.S. Mortensen, J.B. Petersen, M. Busk, and J. Overgaard Imaging hypoxia to improve radiotherapy outcome Nat Rev Clin Oncol 9 2012 674 687
18. 18F]HX4, a promising hypoxia marker for PET imaging Proc Natl Acad Sci U S A 108 2011 14620 14625
19. 18F]HX4: a phase I trial Eur J Nucl Med Mol Imaging 37 2010 1663 1668
20. 18F-HX4 in monkeys and humans determined by using whole-body PET/CT Nucl Med Commun 31 2010 1016 1024
21. L. Chen, Z. Zhang, H.C. Kolb, J.C. Walsh, J. Zhang, and Y. Guan (1)(8)F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with (1)(8)F-FMISO Nucl Med Commun 33 2012 1096 1102
22. 18F] fluoromisonidazole: a pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 1996 417 428
23. W.J. Koh, K.S. Bergman, and J.S. Rasey Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography Int J Radiat Oncol Biol Phys 33 1995 391 398
24. L. Dubois, W. Landuyt, and K. Haustermans Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry Br J Cancer 91 2004 1947 1954
25. A.J. Gray, S. Dische, G.E. Adams, I.R. Flockhart, and J.L. Foster Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations Clin Radiol 27 1976 151 157
26. M.E. Saunders, S. Dische, P. Anderson, and I.R. Flockhart The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum Br J Cancer Suppl 3 1978 268 270
27. N. Abolmaali, R. Haase, and A. Koch Two or four hour [(1)(8)F]FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin 50 2011 22 27
28. 18F- fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer Clin Nucl Med 38 2013 591 596
29. 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer Clin Lung Cancer 11 2010 335 340
30. 18F-FDG PET J Nucl Med 47 2006 1921 1926
31. M.E. Trinkaus, R. Blum, and D. Rischin Imaging of hypoxia with (18) F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy J Med Imaging Radiat Oncol 57 2013 475 481
32. 18F-FAZA) Eur J Nucl Med Mol Imaging 36 2009 1565 1573
33. C. Grau, and J. Overgaard Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay Radiother Oncol 13 1988 301 309
34. S.A. Nehmeh, N.Y. Lee, and H. Schroder Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer Int J Radiat Oncol Biol Phys 70 2008 235 242
35. P. Dirix, V. Vandecaveye, F. De Keyzer, S. Stroobants, R. Hermans, and S. Nuyts Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F- fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI J Nucl Med 50 2009 1020 1027
36. 18F-fluoromisonidazole PET for head and neck cancer J Nucl Med 54 2013 201 207
37. A. van Baardwijk, C. Dooms, and R.J. van Suylen The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer Eur J Cancer 43 2007 1392 1398
38. M.J. Nyflot, P.M. Harari, S. Yip, S.B. Perlman, and R. Jeraj Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx Radiother Oncol 105 2012 36 40
39. R. Boellaard, N.C. Krak, O.S. Hoekstra, and A.A. Lammertsma Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study J Nucl Med 45 2004 1519 1527